Know Cancer

forgot password

Liposuction for Arm Lymphedema Following Breast Cancer Surgery

Phase 2
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Liposuction for Arm Lymphedema Following Breast Cancer Surgery

Inclusion Criteria:

- Patient selection involves identifying women who have undergone breast cancer surgery
in the past and who demonstrate lymphedema (stage 2 or 3) based on arm measurement at
a minimum of 4 different points along the affected arm. Those women with mild to
severe lymphedema with no signs of active infection are candidates for the procedure.
History of previous non-surgical treatment for lymphedema will not preclude entry
into this trial. All patients must be free of active disease recurrence at study
entry. If the lymphedema is of recent onset, then the womans medical oncologist or
primary care physician must rule out an underlying cancer recurrence or blood clot.

- Prior therapy including Manuel Lymph Drainage (MLD) or similar massage method, use of
compression sleeves, and pneumatic pumps is allowable and may be on-going at study
entry. Prior surgical procedures to treat lymphedema such a joining the lymph
channels to the blood vessels at any prior time are not eligible for this study.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%.

- Life expectancy of greater than one year

- Patients must have normal organ and marrow function as defined below:

1. leukocytes ≥3,000/MicroL

2. absolute neutrophil count ≥1,500/MicroL

3. platelets ≥100,000/MicroL

4. total bilirubin within normal institutional limits

5. aspartic transaminase(AST)/alanine transaminase(ALT) ≤2.5 X institutional upper
limit of normal

6. creatinine within normal institutional limits - OR - creatinine clearance ≥60
mL/min/1.73 m² for patients with creatinine levels above institutional normal.

- Able to tolerate general anesthesia and have no recent cardiac history such as
myocardial infarction, congestive heart failure, atrial fibrillation, or angina

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients may not be receiving any other investigational agents.

- Patients with known metastases should be excluded from this clinical trial because of
their poor prognosis.

- History of allergic reactions to compression sleeves, lymphedema bandages, general
anesthetics, and all antibiotics

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because: General Anesthesia and/or
invasive surgical procedures may increase the risk of miscarriage. Secondly,
increased weight during pregnancy may exacerbate lymphedema and thereby make
interpretation of the study endpoints difficult.

- Patients with immune deficiency are at increased risk of lethal infections when
treated with invasive surgical procedures. Secondly, since this is an elective
procedure, the risk to the surgical team of a needle stick would be too high.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

Number of Participants With Desired Response

Outcome Description:

We plan to show the efficacy of liposuction as a treatment for lymphedema. We will contrast the arm volume at 3 months with the baseline value using a paired t-test. Because the change in volume is likely to be proportional to the baseline value, the logarithm of the volumes will be used. With α = .05 and n = 34, we will have 80% power to detect an effect size of 0.5 (that is, a change of 0.5 standard deviations between the baseline and 3-month mean volumes). However since this is a pilot study with limited funding the study will initially open for 7 patients to assess safety and feasibility.

Outcome Time Frame:

3 months per participant

Safety Issue:


Principal Investigator

Christine Laronga, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

H. Lee Moffitt Cancer Center and Research Institute


United States: Institutional Review Board

Study ID:




Start Date:

June 2008

Completion Date:

January 2014

Related Keywords:

  • Breast Cancer
  • Female
  • Lymphedema
  • Breast Neoplasms
  • Lymphedema



H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida  33612